S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
66,000% upside on tiny biotech? (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Indonesia is set to launch Southeast Asia's first high-speed railway, largely funded by China
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
66,000% upside on tiny biotech? (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Indonesia is set to launch Southeast Asia's first high-speed railway, largely funded by China
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
66,000% upside on tiny biotech? (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Indonesia is set to launch Southeast Asia's first high-speed railway, largely funded by China
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
66,000% upside on tiny biotech? (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Indonesia is set to launch Southeast Asia's first high-speed railway, largely funded by China
NASDAQ:MRVI

Maravai LifeSciences (MRVI) Stock Forecast, Price & News

$10.00
+0.40 (+4.17%)
(As of 09/29/2023 ET)
Compare
Today's Range
$9.55
$10.25
50-Day Range
$9.14
$12.48
52-Week Range
$9.09
$26.26
Volume
1.38 million shs
Average Volume
2.11 million shs
Market Capitalization
$2.51 billion
P/E Ratio
17.54
Dividend Yield
N/A
Price Target
$14.10

Maravai LifeSciences MarketRank™ Forecast

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
41.0% Upside
$14.10 Price Target
Short Interest
Healthy
5.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
1.26mentions of Maravai LifeSciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.06) to ($0.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.81 out of 5 stars

Medical Sector

69th out of 972 stocks

Pharmaceutical Preparations Industry

18th out of 449 stocks


MRVI stock logo

About Maravai LifeSciences (NASDAQ:MRVI) Stock

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

MRVI Price History

MRVI Stock News Headlines

Maravai LifeSciences (NASDAQ:MRVI) Stock Price Up 6%
Maravai LifeSciences Hosts 2023 Investor R&D Day
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Maravai LifeSciences (NASDAQ:MRVI) Trading Down 2.4%
Maravai LifeSciences to Host 2023 Investor R&D Day
Elon Did It Again: This Could be Bigger than Tesla
Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.
KeyBanc Downgrades Maravai LifeSciences
See More Headlines
Receive MRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

MRVI Company Calendar

Last Earnings
8/07/2023
Today
10/01/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRVI
Fax
N/A
Employees
660
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.10
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+41.0%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

Net Income
$220.21 million
Pretax Margin
35.25%

Debt

Sales & Book Value

Annual Sales
$883 million
Cash Flow
$1.96 per share
Book Value
$3.55 per share

Miscellaneous

Free Float
250,466,000
Market Cap
$2.51 billion
Optionable
Not Optionable
Beta
-0.23
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Carl W. Hull (Age 64)
    Co-Founder & Exec. Chairman
    Comp: $1.45M
  • Mr. William E. Martin III (Age 48)
    Chief Exec. Officer
    Comp: $2.07M
  • Mr. Kevin M. Herde (Age 51)
    Exec. VP & CFO
    Comp: $778.28k
  • Dr. Peter Michael Leddy Ph.D. (Age 60)
    Exec. VP & Chief Admin. Officer
    Comp: $757k
  • Ms. Christine Dolan (Age 55)
    Chief Operating Officer of Biologics Safety Testing
    Comp: $755.97k
  • Ms. Debra Hart
    Sr. Director of Investor Relations
  • Mr. Kurt Oreshack (Age 42)
    Exec. VP, Gen. Counsel & Sec.
  • Ms. Doreen Pippen
    VP of Marketing
  • Ms. Becky Buzzeo
    Chief Commercial Officer
  • Dr. Kate E. Broderick Ph.D.
    Chief Innovation Officer













MRVI Stock - Frequently Asked Questions

Should I buy or sell Maravai LifeSciences stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last twelve months. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MRVI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRVI, but not buy additional shares or sell existing shares.
View MRVI analyst ratings
or view top-rated stocks.

What is Maravai LifeSciences' stock price forecast for 2023?

9 Wall Street analysts have issued 1 year price targets for Maravai LifeSciences' stock. Their MRVI share price forecasts range from $8.00 to $24.00. On average, they predict the company's share price to reach $14.10 in the next twelve months. This suggests a possible upside of 41.0% from the stock's current price.
View analysts price targets for MRVI
or view top-rated stocks among Wall Street analysts.

How have MRVI shares performed in 2023?

Maravai LifeSciences' stock was trading at $14.31 on January 1st, 2023. Since then, MRVI stock has decreased by 30.1% and is now trading at $10.00.
View the best growth stocks for 2023 here
.

When is Maravai LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our MRVI earnings forecast
.

How were Maravai LifeSciences' earnings last quarter?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) released its quarterly earnings data on Monday, August, 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.04. The business had revenue of $68.91 million for the quarter, compared to analyst estimates of $70.30 million. Maravai LifeSciences had a net margin of 13.88% and a trailing twelve-month return on equity of 20.67%.

What ETFs hold Maravai LifeSciences' stock?
What guidance has Maravai LifeSciences issued on next quarter's earnings?

Maravai LifeSciences issued an update on its FY 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of $0.04-$0.08 for the period, compared to the consensus EPS estimate of $0.29. The company issued revenue guidance of $300.00 million-$325.00 million, compared to the consensus revenue estimate of $403.92 million.

When did Maravai LifeSciences IPO?

(MRVI) raised $1.3 billion in an initial public offering (IPO) on Friday, November 20th 2020. The company issued 50,000,000 shares at $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

What is Maravai LifeSciences' stock symbol?

Maravai LifeSciences trades on the NASDAQ under the ticker symbol "MRVI."

How do I buy shares of Maravai LifeSciences?

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Maravai LifeSciences' stock price today?

One share of MRVI stock can currently be purchased for approximately $10.00.

How much money does Maravai LifeSciences make?

Maravai LifeSciences (NASDAQ:MRVI) has a market capitalization of $2.51 billion and generates $883 million in revenue each year. The company earns $220.21 million in net income (profit) each year or $0.57 on an earnings per share basis.

How many employees does Maravai LifeSciences have?

The company employs 660 workers across the globe.

How can I contact Maravai LifeSciences?

Maravai LifeSciences' mailing address is 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.maravai.com. The company can be reached via phone at 858-546-0004 or via email at ir@maravai.com.

This page (NASDAQ:MRVI) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -